Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Biopharmaceutical medicines, the newest class of therapeutics, are quite heterogeneous and include a range of molecules such as proteins, peptides, vaccines and nucleic acids, with use in virtually all therapeutic fields (e.g. cancer and infectious diseases, vaccination, metabolic dysfunctions) and diagnostics. This edited book gives a concise and up-to-date overview of the biological features justifying the use of different human mucosa as delivery routes for biopharmaceuticals, the technological strategies that have been followed so far regarding the optimization of mucosal potentialities as…mehr
Biopharmaceutical medicines, the newest class of therapeutics, are quite heterogeneous and include a range of molecules such as proteins, peptides, vaccines and nucleic acids, with use in virtually all therapeutic fields (e.g. cancer and infectious diseases, vaccination, metabolic dysfunctions) and diagnostics. This edited book gives a concise and up-to-date overview of the biological features justifying the use of different human mucosa as delivery routes for biopharmaceuticals, the technological strategies that have been followed so far regarding the optimization of mucosal potentialities as well as the challenges that arise with the advent of new biopharmaceutical drugs and alternative means of administration. Following a brief introduction, the first section addresses general aspects of the biology of mucosal tissues and their unique aspects toward beneficial or deleterious interaction with biopharmaceuticals and their delivery systems. The second part reviews the different delivery strategies that have recently been investigated for different mucosal sites. The third section describes the development and clinical applications of drug delivery systems and products enclosing biopharmaceuticals for mucosal delivery, with a focus on the most successful case studies of recent years. The last section briefly centers on relevant aspects of the regulatory, toxicological and market issues of mucosal delivery of biopharmaceuticals. Scientists and researchers in the fields of drug delivery, material science, biomedical science and bioengineering as well as professionals, regulators and policy makers in the pharmaceutical, biotechnology and healthcare industries will find in this book an important compendium of fundamental concepts and practical tools for their daily research and activities.
José das Neves is a researcher at Instituto Superior de Ciências da Saúde-Norte, CESPU, Gandra, and in the Faculty of Pharmacy, University of Porto, Portugal, where he earned a Ph.D. in Pharmaceutical Sciences. His previous work has spanned multiple aspects of the development of vaginal drug delivery systems, and his current research interests include the development of nanotechnology-based solutions for the development of anti-HIV microbicides and mucosal delivery of biopharmaceuticals.
Bruno Sarmento is an affiliated researcher at INEB – Instituto de Engenharia Biomédica, University of Porto, Portugal. He is also an assistant professor of pharmaceutical and biopharmaceutical technology at Instituto Superior de Ciências da Saúde-Norte, CESPU, Gandra, Portugal. He earned a Ph.D. in Pharmaceutical Technology at the University of Porto. He has extensive work in the development of nanocarriers for the oral delivery of biopharmaceuticals—namely insulin—and the establishment of novel in vitro intestinal permeability models. His current research focuses on nanomedicines and their applications in the pharmaceutical and biomedical fields.
Inhaltsangabe
Concepts in Mucosal Immunity and Mucosal Vaccines.- Mucoadhesion and Characterization of Mucoadhesive Properties.- Mucus as a Barrier for Biopharmaceuticals and Drug Delivery Systems.- Epithelial Permeation and Absorption Mechanisms of Biopharmaceuticals.- Oral Delivery of Biopharmaceuticals.- Buccal Delivery of Biopharmaceuticals: Vaccines and Allergens.- Pulmonary Delivery of Biopharmaceuticals.- Nasal Delivery of Biopharmaceuticals.- Ocular Delivery of Biopharmaceuticals.- Vaginal Delivery of Biopharmaceuticals.- Nanoparticles-in-Microsphere Oral Delivery Systems (NiMOS) for Nucleic Acid Therapy in the Gastrointestinal Tract.- Bacteria-Based Vectors for Oral Gene Therapy.- Self-Assembled Polysaccharide Nanogels for Nasal Delivery of Biopharmaceuticals.- Pheroid™ Vesicles and Microsponges for Nasal Delivery of Biopharmaceuticals.- Delivery Strategies for Developing siRNA-Based Vaginal Microbicides.- Delivery Strategies for Developing Vaginal DNA Vaccine Combining Cell-Penetrating Peptides and Jet Injection.- Vaccine Delivery Systems for Veterinary Immunization.- Eligen® Technology for Oral Delivery of Proteins and Peptides.- The RapidMist™ System for Buccal Delivery of Insulin.- The Pharmaceutical Development of rhDNase (Dornase Alpha) for the Treatment of Cystic Fibrosis.- Development of the Exubera® Insulin Pulmonary Delivery System.- Technosphere®: An Inhalation System for Pulmonary Delivery of Biopharmaceuticals.- ChiSys® as a Chitosan-Based Delivery Platform for Nasal Vaccination.- Development of a Cationic Nanoemulsion Platform (Novasorb®) for Ocular Delivery.- Regulatory Aspects and Approval of Biopharmaceuticals for Mucosal Delivery: Quality, Toxicology and Clinical Aspects.
Concepts in Mucosal Immunity and Mucosal Vaccines.- Mucoadhesion and Characterization of Mucoadhesive Properties.- Mucus as a Barrier for Biopharmaceuticals and Drug Delivery Systems.- Epithelial Permeation and Absorption Mechanisms of Biopharmaceuticals.- Oral Delivery of Biopharmaceuticals.- Buccal Delivery of Biopharmaceuticals: Vaccines and Allergens.- Pulmonary Delivery of Biopharmaceuticals.- Nasal Delivery of Biopharmaceuticals.- Ocular Delivery of Biopharmaceuticals.- Vaginal Delivery of Biopharmaceuticals.- Nanoparticles-in-Microsphere Oral Delivery Systems (NiMOS) for Nucleic Acid Therapy in the Gastrointestinal Tract.- Bacteria-Based Vectors for Oral Gene Therapy.- Self-Assembled Polysaccharide Nanogels for Nasal Delivery of Biopharmaceuticals.- Pheroid(TM) Vesicles and Microsponges for Nasal Delivery of Biopharmaceuticals.- Delivery Strategies for Developing siRNA-Based Vaginal Microbicides.- Delivery Strategies for Developing Vaginal DNA Vaccine Combining Cell-Penetrating Peptides and Jet Injection.- Vaccine Delivery Systems for Veterinary Immunization.- Eligen® Technology for Oral Delivery of Proteins and Peptides.- The RapidMist(TM) System for Buccal Delivery of Insulin.- The Pharmaceutical Development of rhDNase (Dornase Alpha) for the Treatment of Cystic Fibrosis.- Development of the Exubera® Insulin Pulmonary Delivery System.- Technosphere®: An Inhalation System for Pulmonary Delivery of Biopharmaceuticals.- ChiSys® as a Chitosan-Based Delivery Platform for Nasal Vaccination.- Development of a Cationic Nanoemulsion Platform (Novasorb®) for Ocular Delivery.- Regulatory Aspects and Approval of Biopharmaceuticals for Mucosal Delivery: Quality, Toxicology and Clinical Aspects.
Concepts in Mucosal Immunity and Mucosal Vaccines.- Mucoadhesion and Characterization of Mucoadhesive Properties.- Mucus as a Barrier for Biopharmaceuticals and Drug Delivery Systems.- Epithelial Permeation and Absorption Mechanisms of Biopharmaceuticals.- Oral Delivery of Biopharmaceuticals.- Buccal Delivery of Biopharmaceuticals: Vaccines and Allergens.- Pulmonary Delivery of Biopharmaceuticals.- Nasal Delivery of Biopharmaceuticals.- Ocular Delivery of Biopharmaceuticals.- Vaginal Delivery of Biopharmaceuticals.- Nanoparticles-in-Microsphere Oral Delivery Systems (NiMOS) for Nucleic Acid Therapy in the Gastrointestinal Tract.- Bacteria-Based Vectors for Oral Gene Therapy.- Self-Assembled Polysaccharide Nanogels for Nasal Delivery of Biopharmaceuticals.- Pheroid™ Vesicles and Microsponges for Nasal Delivery of Biopharmaceuticals.- Delivery Strategies for Developing siRNA-Based Vaginal Microbicides.- Delivery Strategies for Developing Vaginal DNA Vaccine Combining Cell-Penetrating Peptides and Jet Injection.- Vaccine Delivery Systems for Veterinary Immunization.- Eligen® Technology for Oral Delivery of Proteins and Peptides.- The RapidMist™ System for Buccal Delivery of Insulin.- The Pharmaceutical Development of rhDNase (Dornase Alpha) for the Treatment of Cystic Fibrosis.- Development of the Exubera® Insulin Pulmonary Delivery System.- Technosphere®: An Inhalation System for Pulmonary Delivery of Biopharmaceuticals.- ChiSys® as a Chitosan-Based Delivery Platform for Nasal Vaccination.- Development of a Cationic Nanoemulsion Platform (Novasorb®) for Ocular Delivery.- Regulatory Aspects and Approval of Biopharmaceuticals for Mucosal Delivery: Quality, Toxicology and Clinical Aspects.
Concepts in Mucosal Immunity and Mucosal Vaccines.- Mucoadhesion and Characterization of Mucoadhesive Properties.- Mucus as a Barrier for Biopharmaceuticals and Drug Delivery Systems.- Epithelial Permeation and Absorption Mechanisms of Biopharmaceuticals.- Oral Delivery of Biopharmaceuticals.- Buccal Delivery of Biopharmaceuticals: Vaccines and Allergens.- Pulmonary Delivery of Biopharmaceuticals.- Nasal Delivery of Biopharmaceuticals.- Ocular Delivery of Biopharmaceuticals.- Vaginal Delivery of Biopharmaceuticals.- Nanoparticles-in-Microsphere Oral Delivery Systems (NiMOS) for Nucleic Acid Therapy in the Gastrointestinal Tract.- Bacteria-Based Vectors for Oral Gene Therapy.- Self-Assembled Polysaccharide Nanogels for Nasal Delivery of Biopharmaceuticals.- Pheroid(TM) Vesicles and Microsponges for Nasal Delivery of Biopharmaceuticals.- Delivery Strategies for Developing siRNA-Based Vaginal Microbicides.- Delivery Strategies for Developing Vaginal DNA Vaccine Combining Cell-Penetrating Peptides and Jet Injection.- Vaccine Delivery Systems for Veterinary Immunization.- Eligen® Technology for Oral Delivery of Proteins and Peptides.- The RapidMist(TM) System for Buccal Delivery of Insulin.- The Pharmaceutical Development of rhDNase (Dornase Alpha) for the Treatment of Cystic Fibrosis.- Development of the Exubera® Insulin Pulmonary Delivery System.- Technosphere®: An Inhalation System for Pulmonary Delivery of Biopharmaceuticals.- ChiSys® as a Chitosan-Based Delivery Platform for Nasal Vaccination.- Development of a Cationic Nanoemulsion Platform (Novasorb®) for Ocular Delivery.- Regulatory Aspects and Approval of Biopharmaceuticals for Mucosal Delivery: Quality, Toxicology and Clinical Aspects.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497